Almac doubles drug product development capacity; Icon, Tigermed look for Big Data solutions;

> Almac has doubled its drug product development capacity with a new non-GMP formulation facility and two analytical laboratories at its U.K. headquarters. News

> Chinese CRO Tigermed is reaching out to Oracle ($ORCL) to manage the wealth of data generated through its clinical trials, using its Oracle Health Sciences InForm platform to track and verify results. More

> Icon ($ICLR) is teaming up with Cerner, an electronic health records specialist, planning to use the company's software to manage study data. Article

> Drug delivery contractor OctoPlus has inked a Master Service Agreement with Sanofi ($SNY) that covers the development of undisclosed new formulations. Story

> Lonza is looking to double its antibody drug conjugate manufacturing in an effort to reverse the fortunes of one of its Swiss plants. Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.